Chemistry:Ralaniten
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | EPI-002 |
| Drug class | Nonsteroidal antiandrogen |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C21H27ClO5 |
| Molar mass | 394.89 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed.[1] It is a derivative of bisphenol A[2] and one of the four stereoisomers of EPI-001.[1] A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.[3]
See also
References
- ↑ 1.0 1.1 "An androgen receptor N-terminal domain antagonist for treating prostate cancer". The Journal of Clinical Investigation 123 (7): 2948–2960. July 2013. doi:10.1172/JCI66398. PMID 23722902.
- ↑ "A sting in the tail: the N-terminal domain of the androgen receptor as a drug target". Asian Journal of Andrology 18 (5): 687–694. 2016. doi:10.4103/1008-682X.181081. PMID 27212126.
- ↑ "Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer". Current Treatment Options in Oncology 16 (12): 57. December 2015. doi:10.1007/s11864-015-0375-z. PMID 26537882.
 |  |
